HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity by unknown
CASE REPORT
HIV-associated progressive multifocal leukoencephalopathy:
longitudinal study of JC virus non-coding control region
rearrangements and host immunity
Marco Iannetta & Anna Bellizzi & Sara Lo Menzo & Elena Anzivino &
Alessandra D’Abramo & Alessandra Oliva & Claudia D’Agostino &
Gabriella d’Ettorre & Valeria Pietropaolo & Vincenzo Vullo &
Maria Rosa Ciardi
Received: 19 December 2012 /Revised: 15 April 2013 /Accepted: 17 April 2013 /Published online: 29 May 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract John Cunningham virus (JCV), the etiological agent
of progressive multifocal leukoencephalopathy (PML), con-
tains a hyper-variable non-coding control region usually
detected in urine of healthy individuals as archetype form
and in the brain and cerebrospinal fluid (CSF) of PML patients
as rearranged form. We report a case of HIV-related PML with
clinical, immunological and virological data longitudinally
collected. On admission (t0), after 8-week treatment with a
rescue highly active antiretroviral therapy (HAART), the pa-
tient showed a CSF-JCV load of 16,732 gEq/ml, undetectable
HIV-RNA and an increase of CD4+ cell count. Brain magnetic
resonance imaging (MRI) showed PML-compatible lesions
without contrast enhancement. We considered PML-immune
reconstitution inflammatory syndrome as plausible because of
the sudden onset of neurological symptoms after the effective
HAART. An experimental JCV treatment with mefloquine and
mirtazapine was added to steroid boli. Two weeks later (t1),
motor function worsened and MRI showed expanded lesions
with cytotoxic oedema. CSF JCV-DNA increased (26,263
gEq/ml) and JCV viremia was detected. After 4 weeks (t2),
JCV was detected only in CSF (37,719 gEq/ml), and 8 weeks
after admission (t3), JC viral load decreased in CSF and JCV
viremia reappeared. The patient showed high level of immune
activation both in peripheral blood and CSF. He died 4 weeks
later. Considering disease progression, combined therapy fail-
ure and immune hyper-activation, we finally classified the case
as classical PML. The archetype variant found in CSF at t0/t3
and a rearranged sequence detected at t1/t2 suggest that PML
can develop from an archetype virus and that the appearance of
rearranged genotypes contribute to faster disease progression.
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Introduction
Progressive multifocal leukoencephalopathy (PML) is a fatal
brain demyelinating disorder caused by the human polyomavi-
rus JC (JCV), resulting from lytic infection of oligodendrocytes
(Padgett et al. 1971). In the 1980s, PML emerged as a major
complication of HIV infection. The highly active antiretroviral
therapy (HAART) era evidenced PML cases observed in pa-
tients with restored CD4+ T cells count, shortly after HAART
initiation and defined as PML-immune reconstitution inflam-
matory syndrome (IRIS) (Falcò et al. 2008). In addition, PML
cases which cannot be classified either as classic PML or as
PML-IRIS are also reported (Mascarello et al. 2011). The
increasing number of non-HIV/AIDS-related PML cases re-
cently observed among patients treated with the immunomod-
ulatory medications for autoimmune diseases, such as
natalizumab, rituximab and efalizumab, highlighted the role
of the immune system in the pathogenesis of PML (Bellizzi
Marco Iannetta, Anna Bellizzi, Maria Rosa Ciardi and Valeria
Pietropaolo contributed equally to this work.
M. Iannetta :A. Bellizzi : S. Lo Menzo : E. Anzivino :
A. D’Abramo :A. Oliva : C. D’Agostino :G. d’Ettorre :
V. Pietropaolo :V. Vullo :M. R. Ciardi (*)
Department of Public Health and Infectious Diseases,




Department of Obstetrics, Gynecology and Urological Sciences,
“Sapienza” University, Rome, Italy
J. Neurovirol. (2013) 19:274–279
DOI 10.1007/s13365-013-0167-9
et al. 2012). JCV genome contains a well-conserved coding
region and a hyper-variable non-coding control region
(NCCR), which controls the early and late genes transcription
and DNA replication. The well-conserved, non-pathogenic
NCCR called archetype is most often detected in the kidney
and urine of healthy individuals and immunosuppressed pa-
tients with or without PML (Yogo et al. 1991). Conversely,
JCV NCCR rearranged variant showing duplications, tandem
repeats, insertions and deletions is usually found in the blood,
brain and cerebrospinal fluid (CSF) of PML individuals (Tan
et al. 2010). After asymptomatic infection in childhood, JCV
remains quiescent in the kidneys, bone marrow and lymphoid
tissues. In the setting of immunosuppression, the virus may
reactivate whereupon it can migrate into the brain, where
genetic changes occur (neuroadaptation), allowing replication
in the glial cells with PML development (White and Khalili
2011). Nevertheless, it is still debated whether JCV prima-
ry infection is triggered by archetype strain and NCCR
rearrangement occurs during immunosuppression condi-
tions (Fedele et al. 2003), or JCV rearranged form is
required for initial infection in tonsil tissue (Sabath and
Major 2002).
We report a case of JCV archetype-like variants-PML
occurring in an HIV patient, shortly after a rescue HAART
initiation which resulted in a persistent undetectable HIV
viral load.
Case report
A 51-year-old man with HIV-1 infection was admitted to
our unit on March 2012 (t0) because of dysarthria and gait
ataxia. HIV infection diagnosis was made in 2004, with
CD4+ T lymphocytes nadïr of 4 cells/μl (1 %). The patient
experienced multiple HAART failures, and HIV genotyping
test showed a subtype B virus, with resistance mutations for
protease inhibitors, nucleoside/nucleotide reverse transcriptase
inhibitors, non-nucleoside reverse transcriptase inhibitors,
integrase inhibitors and a CXCR4 tropism. On January 2012,
2 months before the onset of neurological symptoms, HIV-
RNAwas 2,527 copies/ml and CD4+ count was 9 cell/μl (2%);
a rescue HAARTwith ritonavir-boosted tipranavir, raltegravir,
enfuvirtide and tenofovir/emtricitabine was started, and after
1 month treatment, HIV-RNA was undetectable (<37
copies/ml) and CD4+ count increased to 23 cells/μl (3.8 %).
On admission (t0), physical examination showed a positive
Romberg’s sign, dysarthria, gait ataxia and a Kurtzke
Expanded Disability Status Scale (EDSS) score of 2.5. HIV-
RNA was still undetectable and CD4+ count was 18 cells/μl
(4 %) (Fig. 1). Brain magnetic resonance imaging (MRI)
showed multiple hyperintense white matter lesions in T2-
weighted turbo spin echo (TSE) sequences and fluid-
attenuated inversion recovery imaging, in the temporal,
cerebellar and pontobulbar regions. Diffusion-weighted imag-
ing (DWI) and apparent diffusion coefficient (ADC) maps
showed the presence of cytotoxic oedema. No contrast en-
hancement was seen in T1-weighted sequences (Fig. 2). CSF
analysis showed normal cell count (2 cells/μl), normal levels
of protein (39 mg/dl) and glucose (43 mg/dl) and normal
results on cytological examination. CSF bacterial and fungal
cultures and cryptococcal antigen were negative as well as
herpes viruses assessed by CSF polymerase chain reaction
(PCR). CSF HIV-RNA was undetectable (<37 copies/ml),
whereas CSF quantitative JCV-DNA was 16,732 gEq/ml.
PML was diagnosed and, suspecting IRIS, 5 days with intra-
venous (IV) methylprednisolone (1 g/day) followed by 8-
week IV methylprednisolone tapered was added to HAART.
Furthermore, after written informed consent, mefloquine
250 mg (guidelines of mefloquine treatment protocol,
Biogen Idec 2012) and mirtazapine 30 mg (once daily) were
administered to our patient, considering the mefloquine inhib-
itory effect on JCV replication in vitro and the mirtazapine
activity in blocking type 2A serotonin cellular receptor for
JCV entry in oligodendrocytes (Marshall and Major 2010).
Clinical, neuroradiological, virological and immunological
parameters were assessed in a longitudinal monitoring at 2
(t1), 4 (t2) and 8 (t3)weeks after admission.
Clinical evaluation at t1 showed worsened motor function,
with difficulties in walking, requiring bilateral aid (EDSS
score 6.5). At t2, dysarthria deteriorated and patient developed
dysphagia and was confined to a wheelchair (EDSSwas 8). At
t3, the patient was aphasic and bedridden and a nasogastric
tube was placed (EDSS was 9.5). Twelve weeks after admis-
sion, he died because of pulmonary oedema (Fig. 1).
MRI performed at t1, t2 and t3 showed a progressive
extension of the lesions previously described, with cytotoxic
oedema on DWI sequences and ADC maps. There was no
mass effect or contrast enhancement in all the T1-weighted
images performed (Fig. 2).
HIV viral load was persistently undetectable in plasma and
CSF samples. Conversely, a JC viral load of 26,263 gEq/ml in
the CSF and 4,333 gEq/ml in the plasma was found at t1
(Fig. 1). At t2, CSF JCV load increased up to 37,719 gEq/ml
whilst plasma resulted negative. Finally at t3, the CSF JC viral
load decreased to 6,681 gEq/ml and JCV-DNA reappeared in
plasma with 1,000 gEq/ml. In all urine samples, JCV was
persistently negative (Fig. 1).
JCV NCCR sequence analysis was performed in all sam-
ples as well as in peripheral blood mononuclear cells (PBMC)
by real-time quantitative PCR (Q-PCR). Sequencing of PCR
products was directly performed by using primers previously
reported (Pietropaolo et al. 2003). JCV archetype variant was
found in CSF specimens collected at t0 and t3, in plasma at t1
and t3 and in PBMCs at t0, t1 and t3. CSF samples collected at
t1 and t2 showed a JCV NCCR rearranged sequence
characterised by a duplication of the box C, containing the
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cre-TAR binding site for the HIV-tat protein (Fig. 3). In addi-
tion, JCV subtype 1B was found in all JCV-DNA-positive
samples, performing direct sequencing of a 215-bp fragment
amplified from the major capsid protein (VP1) gene (Agostini
et al. 2001).
Our patient had a very low CD4+ cell count in peripheral
blood, with CD4/CD8 ratio ranging from 0.04 to 0.05. The
same finding was observed in CSF, with a CD4/CD8 ratio
ranging from 0.12 to 0.22. During follow-up, high levels of
immune activation (defined by flow cytometry as percent-
age of double positive HLA-DR and CD38) were observed
for CD4+ and CD8+ T lymphocytes, both in peripheral
blood and CSF samples.
Discussion
Our patient developed PML after 2 months of an effective
rescue HAART, resulting in undetectable HIV-RNA and
initial rise of CD4+ cell count (100 % increase). In this
scenario, the sudden onset of neurological symptoms and
signs shortly after HAART, without other cerebral
disorder, led us to consider PML-IRIS as plausible
(Cinque et al. 2009; Gheuens et al. 2012; Harrison et al.
2011). Although MRI performed four times did not show
brain lesions enhancement in T1 sequences after contrast
administration (a strong suggestion of blood–brain barrier
disruption and inflammation indicating IRIS), PML-IRIS
was still considered, based on a retrospective analysis
showing MRI contrast enhancement of brain PML lesions
occurring only in 56.7 % of PML-IRIS cases (Tan et al.
2009). Hence, an experimental JCV combined treatment
with mefloquine and mirtazapine was added to steroid boli
but failed to alter disease progression. CSF JCV viral load
remained persistently elevated and JCV remained detect-
able in the plasma.
T cell activation seems to be the primary characteristic
that defines pathogenic versus non-pathogenic SIV infection
in non-human primates models (Silvestri et al. 2007).
Among untreated HIV+ patients, T cell activation has been
found as an independent predictor of disease progression
(Giorgi et al. 2002). In treated subjects, T cell activation is
associated with lower CD4+ T cell gains during treatment
(Hunt et al. 2003). During suppressive HAART, high level
Fig. 1 Clinical, immunological,
virological and therapeutic
history of the patient. The figure
shows the clinical evolution we
observed in our patient, from
admission to death, according to
the EDSS scale.We reported also
the virological and
immunological findings during
hospitalisation. The arrows in
the lower part of the figure
represent the duration of
HAART, mirtazapine and
mefloquine experimental therapy
and steroid treatment. JCV Q-
PCR was performed on
cerebrospinal fluid (CSF),
plasma and urine samples and
the JCV load is indicated in
equivalent genome (gram
equivalent per millimetre).
Undet., HIV load <37 copies/ml
in the CSF and plasma. Neg,
negative. t0, 8 weeks after
starting the rescue HAART
(hospital admission); t1,
10 weeks after starting the rescue
HAART (2 weeks after hospital
admission); t2, 12 weeks after
starting the rescue HAART
(4 weeks after hospital
admission); t3, 16 weeks after
starting the rescue HAART
(8 weeks after hospital
admission)
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of immune activation is predictive of mortality due to AIDS-
and non-AIDS-defining clinical events (Butler et al. 2011).
In our patient, high level of CD4+ and CD8+ T lympho-
cyte immune activation were persistently observed. On the-
se assessments, it was hard to classify this case as either
classical PML or IRIS, therefore emphasising the need for
new diagnostic tools to better differentiate the two PML
forms. Despite that proton magnetic resonance spectroscopy
has been recently reported as useful to identify PML-IRIS
lesions by their metabolism (Gheuens et al. 2012),
unfortunately we were unable to perform spectroscopy in
our patient.
JCV NCCR rearranged form was detected in the CSF
samples collected at t1 and t2 and it was characterised by a
duplication of the box C containing the cre-TAR binding site
for the HIV-tat protein. Tan et al. (2010) have also found a
similar rearranged sequence and the JCV NCCR archetype in
the brain of HIV-positive patients with PML. We directly
performed the sequencing of PCR products, detecting only
the main JCV variant produced by the lytic infection of brain
Fig. 2 MRI evolution of the
brain lesions. A–D, T2-TSE
sequences showing the
evolution of the left cerebellar
lobe lesion (arrows) from t0 to
t3. E–H, T2-TSE sequences
showing the evolution of the
lesion of the pons (arrows)
from t0 to t3. No mass effect
was seen in all the images
collected. I–L, post-contrast T1-
weighted sequences
demonstrating the absence of
contrast enhancement (arrows)
in the left cerebellar lobe lesion
(MRI). All the white matter
lesions did not show
enhancement in T1-weighted
sequences after contrast
administration. The lack of
mass effect and contrast
enhancement in all the MRI
performed from t0 to t3 reduced
the reliability of an IRIS-PML,
which is usually characterised
by a strong inflammatory
infiltration of tissues,
determining an alteration of
blood–brain barrier which
translates in penetration of
contrast inside the lesions and
oedema, which is the cause of
mass effect
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cells at any given time. Therefore in our patient, we cannot
conclude whether the rearrangements at times t1 and t2 may be
generated from the archetypal variant found at t0 or more viral
variants established latency in the glial cells. Nevertheless, our
data showed the strict association between the presence of the
JCV rearranged forms in CSF and the clinical worsening,
confirming their role in PML pathogenesis.
Finally, the finding of the archetype variant, in associa-
tion with a relative lower number of JC viral load in CSF at
t0 and t3, requires a reassessment of the archetypal JCV
strain role in the lytic infection of brain cells. In fact in a
recent report, Dang et al. (2012) focused on a novel JCV
variant, harbouring an archetype-like NCCR, in a patient
affected by JCV encephalopathy. In our case, it seems reli-
able that PML came out as local brain reactivation of latent
virus since a conserved NCCR archetype form was detected
in the plasma and PBMC throughout the observation period.
It is noteworthy that the JCV rearranged variant detected
in our patient showed a duplication of HIV-tat binding
region, despite undetectable HIV-RNA in CSF sample.
Viral proteins, such as tat, may be the results of transcription
of both integrated and unintegrated HIV-DNA, and the latter
could increase after the initiation of HAART containing an
integrase inhibitor (Sloan and Wainberg 2011).
It is interesting to note that JCV-DNAwas never detected
in urine samples of our patient despite the severe
immunosuppressed status. Studies specifically focused on
the pathogenesis of PML suggest that JCV reactivation in
the kidney may not be related to PML (Koralnik et al. 1999),
and no association between JCV viruria and subject’s im-
munological status has been demonstrated (Marzocchetti et al.
2009). Finally, JCV subtype 1B, the predominant genotype in
Southwest Europe (Agostini et al. 2001), was detected,
suggesting JCV primary infection as acquired in Italy.
In conclusion, this case suggests that when a severe
HIV-related immune deficiency occurs, JCV archetypal
strain harbouring the brain in a latent state may repli-
cate causing brain white matter lesions resulting in
PML. Hence, JCV NCCR rearrangement seems not re-
quired to trigger JCV brain infection but its occurrence
may worsen the PML’s clinical course. More studies are
needed to fulfil the comprehension of JCV archetype
variant role in the PML pathogenesis and the factors
regulating NCCR rearrangement in vivo.
Fig. 3 PML-associated variant Mad-1 (A), archetype CY (B) and JCV
NCCR structures found in samples (C, D). The nucleotide sequences are
shown from the core of the origin of DNA replication (ori) to the start site
of the late leader protein, Agno protein. In A, the nucleotide numbering is
based on PML-associated variant Mad-1 NCCR sequence and numbers
are indicated in bold and black. In B, the nucleotide numbering of the
archetype sequence of Japanese strain CY, isolated by Yogo et al. (1991)
is reported in bold and grey. InC, the archetype variant sequence found in
CSF specimens collected at t0 and t3, in plasma at t1 and t3 and in PBMC
at t0, t1 and t3 is reported. In D, the rearranged JCV NCCR sequence of
308 bp in length, obtained from the CSF samples collected at t1and t2, is
showed. Asterisks represent single nucleotide point mutations or dele-
tions. The TATA box is presented by TATA. Italicised capital letters
indicate nucleotides. Mad-1 NCCR contains an adenine at positions 85
and 183, compared with archetype CYNCCR, which contains guanine at
these positions. Boxes division from A to F is also shown in capital
letters. The sequence analysis was performed directly on DNA template
previously amplified by nested-PCR, using two pairs of primers that
anneal to the invariant regions flanking the NCCR of JCV. Primers
BKTT1 (5′-AAG GTC CAT GAG CTC CAT GGA TTC TTC C-3′)
and BKTT2 (5′-CTA GGT CCC CCA AAA GTG CTA GAGCAG C-
3′) amplified a 724-bp DNA fragment in JCV (Mad-1). The second pair,
JC1 (5′-CCT CCA CGC CCT TAC TAC TTC TGA G-3′) and JC2 (5′-
AGC CTG GTG ACA AGC CAA AAC AGC TCT-3′), amplified a
portion of the first round PCR product, generating a fragment of 308 bp
(Pietropaolo et al. 2003)
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